Therapeutic vaccines: advances in understanding of appropriate patient selection and trial design

Dr James Gulley, Director, Clinical Trials Group & Deputy Chief, Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health joined us at the World Vaccine Congress Washington to lead the discussion of appropriate patient selection and trial design in the production of therapeutic vaccines.  His conclusions included: • Appropriate endpoints      – Kinetics …

Patient selection & successful outcomes

Dr Robert Petit, Vice President of Clinical Operations and Medical Affairs, Advaxis joined us at the World Vaccine Congress Washington 2012 to answer the following question: Why does patient selection matter? Simply, because each patient factor can impact the outcome. Patient factors can include: age, performance status, gender, race, disease status etc. Critical patient selection factors can vary by disease …